

DOCKET NO.: RTS-0332

"Express Mail" Label No.: EV053176185US

Date of Deposit: 12-5-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Frank Bennett et al.

Serial No.: Not yet assigned Group No.: Not yet assigned

Filed: herewith

For: **Antisense Modulation of MHC class II transactivator Expression**

BOX SEQUENCE

Assistant Commissioner for Patents
Washington DC 20231



INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above identified application, no additional fee is required.

Copies of each of the references listed on the attached Form PTO-1449 are enclosed.

Date: December 4, 2001

Respectfully submitted,

Donna T. Ward

Registration No. 48,271

ISIS PHARMACEUTICALS, INC.
Carlsbad Research Center
2292 Faraday Avenue
Carlsbad, CA 92008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: C. Frank Bennett and Kenneth W. Dobie

For: Antisense Modulation of MHC class II transactivator Expression

BOX SEQUENCE

Assistant Commissioner for Patents

Washington DC 20231

J1000 U.S. PTO
10/006366
11/05/01PATENT APPLICATION TRANSMITTAL LETTER

attachment

Transmitted herewith for filing, please find the following:

- The specification of the above-referenced patent application;
- An **executed** Declaration or Oath and Power of Attorney;
- An Assignment of the invention to Isis Pharmaceuticals Inc. with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR §§ 1.821 through 1.825;
- Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- An Information Disclosure Statement with references; and
- Applicant claims small entity status pursuant to 37 CFR § 1.27.

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Rate	Fee
BASE FEE				\$370.00
Total Claims	20 - 20 =	0	X \$9=	\$0
Indep. Claims	2 - 3 =	0	x\$40=	\$0
			TOTAL	\$ 370.00

The Commissioner is hereby authorized to charge the following fees to Deposit Account No. 500252:

- the amount of \$410.00 for the above listed fees;
- payment of the following fees associated with this communication or credit any overpayment;
- any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed

Date: December 5, 2001

Donna T. Ward

Registration No. 48,271

Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Jane Massey Licata or Kathleen A. Tyrrell
Licata & Tyrrell, P.C.
66 East Main Street
Marlton NJ 08053
(856) 810-1515

Form PTO-1449 Modified	Docket No. RTS-0332	Serial No. <i>10/006,366</i>
List of Patents and Publications Cited by Application (Use several sheets if necessary)	Applicant C. Frank Bennett et al.	
U.S. Department of Commerce Patent and Trademark Office	Filing Date	Group <i>1635</i>

U.S. PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Name	Class	Subclass
<i>KAL</i>	AA	5,672,473	9/30/1997	Glimcher et al.	435	6
<i>KAL</i>	AB	5,994,082	11/30/1999	Mach	435	7.1
<i>KAL</i>	AC	5,944,505	11/30/1999	Ting et al.	530	350
<i>KAL</i>	AD	6,022,741	2/8/2000	Ting et al.	435	366
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					

FOREIGN PATENT DOCUMENTS

Examiner's Initial		Document No.	Date	Country	Translation YES NO
<i>KAL</i>	AO	WO 98/15626	4/16/1998	PCT	X
	AP	EP 0874049	10/28/1998	EP	X
<i>KAL</i>	AQ	WO 98/25968	6/18/1997	PCT	X
	AR				
	AS				
	AT				
	AU				
	AV				
	AW				
	AX				

EXAMINER <i>Karen A. Jacono</i>	DATE CONSIDERED <i>06-04-03</i>
---------------------------------	---------------------------------

DOCKET NO.: RTS-0332

"Express Mail" Label No.: EV053176185
Date of Deposit: 12/5/2001J1000 U.S. PAT.
10/006366
11/05/01

Form PTO-1449 Modified		Docket No. RTS-0332	Serial No. not yet assigned
List of Patents and Publications Cited by Application (Use several sheets if necessary)		Applicant C. Frank Bennett et al.	
		Filing Date herewith	Group 1635
U.S. Department of Commerce Patent and Trademark Office			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
KAL	AA	Bontron et al., Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A, Hum. Genet., 1997, 99:541-546	
	AB	Charreau et al., Cyclosporine inhibits class II major histocompatibility antigen presentation by xenogeneic endothelial cells to human T lymphocytes by altering expression of the class II transcriptional activator gene, Transplantation, 2000, 70:354-361	
	AC	Chin et al., Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction, Immunity, 1994, 1:687-697	
	AD	Cressman et al., Mechanisms of nuclear import and export that control the subcellular localization of class ii transactivator, J. Immunol., 2001, 167:3626-3634	
	AE	Harton et al., GTP binding by class II transactivator: role in nuclear import, Science, 1999, 285:1402-1405	
	AF	Harton et al., Class II transactivator: mastering the art of major histocompatibility complex expression, Mol. Cell. Biol., 2000, 20:6185-6194	
	AG	Itoh-Lindstrom et al., Reduced IL-4-, lipopolysaccharide-, and IFN-gamma-induced MHC class II expression in mice lacking class II transactivator due to targeted deletion of the GTP-binding domain, J. Immunol., 1999, 163:2425-2431	
	AH	Kielar et al., Nitric oxide inhibits INFgamma-induced increases in CIITA mRNA abundance and activation of CIITA dependent genes--class II MHC, Ii and H-2M. Class II TransActivator, Inflammation, 2000, 24:431-445	
✓	AI	Kwak et al., The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells, Swiss Med. Wkly., 2001, 131:41-46	
EXAMINER Kara A. Jaconine		DATE CONSIDERED 06-04-03	

DOCKET NO.: RTS-0332

Form PTO-1449 Modified		Docket No. RTS-0332	Serial No. not yet assigned 10/006,366
List of Patents and Publications Cited by Application (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Applicant C. Frank Bennett et al.	
		Filing Date herewith	Group 1635
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
KAR	AS	Zhu et al., Transcriptional scaffold: CIITA interacts with NF-Y, RFX, and CREB to cause stereospecific regulation of the class II major histocompatibility complex promoter, Mol. Cell. Biol., 2000, 20:6051-6061	
EXAMINER Karen A. Giacomin		DATE CONSIDERED 06-04-03	